NHS
UK government spends £300 million on dementia
February 23, 2015Research and Development, Sales and Marketing Cameron, England, NHS, dementia, investment, research
UK prime minister David Cameron has said the government is to invest more than £300m into dementia research and that …
NICE is ‘setting prices too high’ for NHS
February 19, 2015Sales and Marketing ABPI, NHS, NICE, QALY, costs, health, pharma
The cost threshold NICE uses when approving drugs is too high and is doing more harm than good, new research …
NICE unveils guidelines to monitor antibiotic prescribing
February 18, 2015Sales and Marketing AMR, Antibiotics, GPs, NHS, NICE, antimicrobials, baker
NICE are asking UK doctors to spy on their colleagues in order to help tackle the growing threat of antimicrobial …
Celgene’s blood cancer pill too expensive for NHS
February 13, 2015Sales and Marketing Celgene, NHS, NICE, Pomalidomide, imnovid, myeloma
NICE has decided not to recommend Celgene’s Imnovid for treating patients with multiple myeloma – a cancer that affects white …
New support guidelines for NHS whistleblowers
February 12, 2015Medical Communications, Sales and Marketing CCG, Jeremy Hunt, NHS, comms, robert francis, whistleblowers
New guidelines to support NHS whistleblowers have been proposed by Sir Robert Francis QC – who led the inquiry into …
NHS reform was ‘distracting and damaging’
February 6, 2015Sales and Marketing CDF, Cameron, NHS, UK, coalition, healthcare, king's fund
Healthcare think tank The King’s Fund has said through a report that organisational changes to the NHS under the coalition …
Stephen Whitehead: pharma has transformed
February 2, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, CDF, NHS, NICE, PPRS, Stephen Whitehead, lgbt, pharma
According to The Association of the British Pharmaceutical Industry (ABPI) the dominant issue in 2015 will be the affordability and …
Patients lack data confidence in NHS
January 30, 2015Medical Communications, Sales and Marketing Astellas, NHS, care data, data, online, privacy
A recent pharma survey has found that a majority of Britons lack confidence in the NHS to keep their personal …
NICE approves world’s most expensive drug
January 28, 2015Sales and Marketing Alexion, Dillon, NHS, NICE, aHUS, eculizumab, hst, soliris
The world’s most expensive drug has been approved in final guidance from NICE, making it the first drug to pass …
CDF chair: more treatment reviews to come
January 16, 2015Sales and Marketing CDF, Cancer Drugs Fund, NHS, NHS England, NICE, peter clark
The chair of NHS England’s cancer drugs fund has said there is likely to be more reviews of affordable treatments …
Janssen privy to new pricing scheme and see NICE nod
January 16, 2015Sales and Marketing Janssen, NHS, NICE, hep C, hepatitis, olysio, ribavirin, simeprevir
Janssen’s hepatitis C drug Olysio has been approved by NICE whilst also reaching a novel ‘pay if you clear’ pricing …
NICE approves Sovaldi
January 16, 2015Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, pharma, sofosbuvir, sovaldi
NICE has recommended Sovaldi in final draft guidance and extended its scope, despite concerns over the price of the blockbuster …
NICE releases reflux disease guidelines
January 15, 2015Sales and Marketing NHS, NICE, UK, gor, gord, h2ra
NICE has released new guidelines providing doctors with advice on how to treat gastro-oesophageal reflux disease (GORD) in young people. …
Another NICE no for Dendreon cancer drug
January 13, 2015Sales and Marketing Cancer, Dendreon, FDA, NHS, NICE, Provenge, sipuleucel-T
Dendreon has seen its prostate cancer treatment for people whose disease has spread and who are not yet suitable for …
NHS drops 25 treatments from Cancer Drugs Fund
January 12, 2015Sales and Marketing Afinitor, CDF, Cancer, Cancer Drugs Fund, Eisa, Halaven, Heribulin, Jevtana, NHS, Sanofi, Zaltrap, aflibercept, cabazitaxel, everolimus
Twenty-five cancer treatments will be removed from the Cancer Drugs Fund list, NHS England has announced. Having concluded its review …
Latest content
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
